High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma

Liver International

Volumn 25, Issue 2, 2005, Pages 266-272

  Yeo, Winnie ^a   Wong, Nathalie ^a   Wong, Wai Lap ^a   Lai, Paul B S ^a   Zhong, Sheng ^a   Johnson, Philip J ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Epigenetic; Liver cancer Tissues; Plasma; Promoter methylation; RASSF1A

Indexed keywords

ALPHA FETOPROTEIN; DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; AGED; ARTICLE; CANCER SCREENING; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; FREQUENCY ANALYSIS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN METHYLATION; TISSUE DISTRIBUTION; TUMOR VOLUME;

BASE SEQUENCE; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 17044387017     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01084.x     Document Type: Article

References (32)

1. Schafer D F, Sorrell M F. Hepatocellular carcinoma. Lancet 1999; 353: 1253-17.
2. Beassley R P, Hwang L Y, Lin C C, Chein C S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet 1981; ii: 1129-33.
3. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S, Zhu J. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002; 2(1): 29-42.
4. Wong I, Lo Y M, Yeo W, Lay W Y, Johnson P J. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000; 6: 3516-21.
5. Wong I H, Lo Y M, Zhang J, Liew C T, Ng M H L, Wong N, Lai P B, Lau W Y, Hjelm M, Johnson P J. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999; 59: 71-3.
6. Burbee D G, Forgacs E, Zochbauer-Miller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar A F, Lerman M I, Zabarovsky E, White M, Minna J D. Epigenetic alteration of RASSFIA in lung cancers and malignant phenotypes suppression. J Nail Cancer Inst 2001; 93(9): 691 9.
7. Dammann R, Li C, Yoon J H, Chin P L, Bates S, Pfeifer G P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315-9.
8. Kok K, Naylor S L, Buys C H. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 1997; 71: 27-92.
9. Daigo Y, Nishiwaki T, Kawasoe T, et al. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res 1999; 59(9): 1966-72.
10. Baylin S B, Herman J G, Graff J R, Vertino P M, Issa J P. Alteration in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-96.
11. Lo K, Kwong J, Hui A, Chan S, To K, Chan A, Chow L, Teo P, Johnson P, Huang D. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61: 3877-81.
12. Agathanggelou A, Honorio S, MaCartney D P, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw J A, Hosoe S, Lerman M I, Minna J D, Maher E R, Latif F. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001; 20: 1509-18.
13. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology 2000; 32: 970-9.
14. Scdhagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer G P, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 2002; 62: 3698-701.
15. Wong N, Lai P, Lee S, Fan S, Pang E, Liew C, Zhong S, Lau J W, Johnson P J. Assessment of genetic changes in hepatocellular carcinoma by comparative genomic hybridization analysis: relationship to disease stage, tumor size, and cirrhosis. Am J Pathol 1999; 154(1): 37-43.
16. Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997; 18: 59-65.
17. Lin Y W, Sheu J C, Huang G T, Lee H S, Chen C H, Wang J T, Lee P H, Lu F J. Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridization in Taiwan. Eur J Cancer 1999; 35: 652-8.
18. Sheu J C, Lin Y W, Chou H C, Huang G T, Lee H S, Lin Y H, Huang S Y, Chen C H, Wang J T, Lee P H, Lin J T, Lu F J, Chen D S. Loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in Taiwan. Br J Cancer 1999; 80(3-4): 468-76.
19. Zhang Y J, Ahsan H, Chen Y, Lunn R M, Wang L Y, Chen S Y, Lee P H, Chen C J, Santella R M. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002; 35(2): 85-92.
20. Zhong S, Yeo W, Tang M W, Wong N, Lai P B S, Johnson P J. Intensive hypermethylation of the CpG island of ras association domain family 1A (RASSF1A) in HBV-associated hepatocellular carcinomas. Clin Cancer Res 2003; 9(9): 3376-82.
21. Lee T L, Leung W K, Chan M W Y, Ng E K W, Tong J H M, Lo K W, Chung S S C, Sung J J Y, To K F. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002; 8: 1761-66.
22. Silva J M, Dominguez G, Garcia J M, Gonzalez R, Villanueva M J, Navarro F, Provencio, M, San Martin S, Espana P, Bonilla F. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999; 59: 3251-6.
23. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin S B, Herman J G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70.
24. Sanchez-Cespedes M, Estellar M, Wu L, Nawroz-Danish H, Yoo G H, Koch W M, Jen J, Herman J G, Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2001; 60: 892-5.
25. Chan M W, Chan L W, Tang N L, Lo K W, Tong J H, Chan A W, Cheung H Y, Wong W S, Chan P S, Lai F M, To K F. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003; 104(5): 611-6.
26. Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher E R, Latif F. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003; 22(1): 147-50.
27. Belinsky S A, Palmisano W A, Gilliland F D, Crooks L A, Divine K K, Winters S A, Grimes M J, Harms H J, Tellez C S, Smith T M, Moots P P, Lechner J F, Stidley C A, Crowell R E. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002; 62(8): 2370-7.
28. Wong N, Li L, Tsang K, Lai P B S, To K F, Johnson P J. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002; 37: 633-9.
29. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe H H, Pfeifer G P, Schlegelberger B, Dammann R. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003; 22(12): 1866-71.
30. Wong I H N, Chan J, Wong J, Tam P K H. Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res 2004; 10: 994-1002.
31. Yan P S. Shi H, Rashmatpanah F, Hsiau H A. Lau Y W, Liu J C, Huang T H M. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res 2003; 63: 6178-86.
32. Graff J R, Herman G J, Myohanen S, Baylin S B, Vertino P M. Mapping of patterns CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997; 272: 22322-9.